Eagle Pharmaceuticals, Inc. (EGRX) Rating Reiterated by Piper Jaffray Companies

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)‘s stock had its “buy” rating reiterated by equities research analysts at Piper Jaffray Companies in a research note issued to investors on Friday. They currently have a $75.00 target price on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target indicates a potential upside of 34.77% from the stock’s current price.

Other research analysts have also issued reports about the company. BidaskClub lowered Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Zacks Investment Research lowered Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 31st. Mizuho dropped their price objective on Eagle Pharmaceuticals from $57.00 to $40.00 and set an “underperform” rating for the company in a research note on Thursday, July 27th. ValuEngine upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Finally, Royal Bank Of Canada dropped their price objective on Eagle Pharmaceuticals from $94.00 to $81.00 and set an “outperform” rating for the company in a research note on Thursday, July 27th. Three investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $72.50.

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) traded up 2.90% during trading on Friday, hitting $55.65. 390,342 shares of the stock traded hands. Eagle Pharmaceuticals has a 52 week low of $45.05 and a 52 week high of $97.15. The company has a market cap of $844.15 million, a price-to-earnings ratio of 9.34 and a beta of 1.31. The firm’s 50-day moving average price is $56.36 and its 200-day moving average price is $68.17.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.18). Eagle Pharmaceuticals had a return on equity of 66.30% and a net margin of 39.32%. The company had revenue of $50.10 million for the quarter, compared to analyst estimates of $52.52 million. During the same quarter in the prior year, the company earned $0.80 earnings per share. The business’s revenue was up 22.5% compared to the same quarter last year. On average, equities research analysts anticipate that Eagle Pharmaceuticals will post $3.79 earnings per share for the current year.

Eagle Pharmaceuticals announced that its Board of Directors has approved a stock repurchase program on Wednesday, August 9th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the specialty pharmaceutical company to buy up to 13.3% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “Eagle Pharmaceuticals, Inc. (EGRX) Rating Reiterated by Piper Jaffray Companies” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/10/29/eagle-pharmaceuticals-inc-egrx-rating-reiterated-by-piper-jaffray-companies.html.

In other Eagle Pharmaceuticals news, Director Douglas L. Braunstein bought 20,400 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The shares were bought at an average price of $49.07 per share, for a total transaction of $1,001,028.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 19.50% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Kopp Investment Advisors LLC grew its holdings in shares of Eagle Pharmaceuticals by 0.3% during the second quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock worth $241,000 after purchasing an additional 10 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of Eagle Pharmaceuticals by 0.3% during the second quarter. Alps Advisors Inc. now owns 5,985 shares of the specialty pharmaceutical company’s stock worth $472,000 after purchasing an additional 16 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Eagle Pharmaceuticals by 0.7% during the second quarter. PNC Financial Services Group Inc. now owns 11,269 shares of the specialty pharmaceutical company’s stock worth $889,000 after purchasing an additional 82 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Eagle Pharmaceuticals by 2.4% during the first quarter. Arizona State Retirement System now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $348,000 after purchasing an additional 100 shares during the last quarter. Finally, D.A. Davidson & CO. grew its holdings in shares of Eagle Pharmaceuticals by 2.4% during the second quarter. D.A. Davidson & CO. now owns 4,350 shares of the specialty pharmaceutical company’s stock worth $343,000 after purchasing an additional 100 shares during the last quarter.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

What are top analysts saying about Eagle Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eagle Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit